E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose (MTD) as defined by the dose-limiting toxicity (DLT) of E7080 in combination with carboplatin and paclitaxel.
Oncology Clinical Development Section. JAC PCU. Eisai Co., Ltd.
Japan: Ministry of Health, Labor and Welfare